"10.1371_journal.pone.0138646","plos one","2015-09-25T00:00:00Z","Yuejun Liu; Aurélie Cotillard; Camille Vatier; Jean-Philippe Bastard; Soraya Fellahi; Marie Stévant; Omran Allatif; Clotilde Langlois; Séverine Bieuvelet; Amandine Brochot; Angèle Guilbot; Karine Clément; Salwa W Rizkalla","Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique—Hôpitaux de Paris, Heart and Nutrition Department, Pitié-Salpêtrière Hospital, and Human Nutrition Research Center—Ile de France, 75013, Paris, France; INSERM, UMR S U1166, Nutriomics, 75013, Paris, France; Sorbonne University, Pierre and Marie Curie University, Paris 06, UMR_S 1166 I, Nutriomics Team, Paris, France; Assistance Publique-Hôpitaux de Paris, Biochemistry and Hormonology Department, Tenon Hospital, 75970, Paris, France; AdipoPhYt, 75013, Paris, France; Groupe PiLeJe, 75015, Paris, France","Conceived and designed the experiments: KC SWR SB. Performed the experiments: SWR YL CV. Analyzed the data: AC YL OA. Contributed reagents/materials/analysis tools: SF JPB MS. Wrote the paper: SWR YL KC. Formulation of the test product: CL. Represented the study sponsor and participated in study management: AG SB AB. Contributed to critical revision of the manuscript for important intellectual content and approved the final manuscript: SWR YL AC CV JPB SF MS OA CL SB AB AG KC. Had final responsibility for the decision to publish the findings: SWR YL AC CV JPB SF MS OA CL SB AB AG KC.","PileJe (Saint-Laurent-des-Autels, France) provided funding towards this study. SB, AG and CL are employed by PiLeJe; AC received a grant from PiLeJe, OA and YL received fees for data management and other study procedures on the behalf of PiLeJe, MS is employed by AdipoPhYt at the time of the study. There are no patents or products in development to declare. The tested product was marketed before the beginning of the study. Other: CV has received consultancy fees from AstraZeneca and Sanofi, support for travel and congress inscription from Novonordisk and Sanofi, and research materials from AstraZeneca; JPB has received speaker fees from the European Group for the Study of Insulin Resistance (EGIR) and from Servier and a research grant from the Association Nationale de la Recherche sur le SIDA (ANRS); SF has received support for congress attendance from Beckman Coulter; the other authors declare no conflict of interest. The above declarations have no effect on the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2015","09","Yuejun Liu","YL",13,TRUE,3,3,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
